Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $10.59, for a total transaction of $17,314.65. Following the completion of the sale, the insider directly owned 3,594 shares of the company’s stock, valued at $38,060.46. This trade represents a 31.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Scott Bizily also recently made the following trade(s):

• On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00.
• On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.17, for a total transaction of $16,627.95.
• On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $24,080.00.
• On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00.

4D Molecular Therapeutics Price Performance

NASDAQ:FDMT opened at $10.34 on Friday. The firm has a 50-day moving average of $9.60 and a two-hundred day moving average of $6.46. The stock has a market cap of $590.72 million, a P/E ratio of -2.76 and a beta of 2.96. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.23 and a 1-year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%.The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.40 million. As a group, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on FDMT. Roth Capital cut their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Wall Street Zen upgraded shares of 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Barclays cut their price target on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Leerink Partners reissued an “outperform” rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Finally, Royal Bank Of Canada upped their target price on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.70.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently added to or reduced their stakes in FDMT. Y Intercept Hong Kong Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the first quarter worth $41,000. Proficio Capital Partners LLC grew its position in shares of 4D Molecular Therapeutics by 26.0% during the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock valued at $75,000 after buying an additional 5,195 shares during the last quarter. Federated Hermes Inc. raised its stake in 4D Molecular Therapeutics by 33,131.8% during the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock worth $4,038,000 after acquiring an additional 1,246,419 shares during the period. Privium Fund Management B.V. lifted its holdings in 4D Molecular Therapeutics by 8.3% in the first quarter. Privium Fund Management B.V. now owns 131,000 shares of the company’s stock worth $423,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of 4D Molecular Therapeutics by 318.3% during the first quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock valued at $380,000 after purchasing an additional 89,611 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.